Jun. 18 at 1:02 PM
$MDWD
The point that catches my attention most is not Solventum’s involvement, but Mölnlycke already owning 10% and having years of direct exposure to NexoBrid. Historically, strategic investors often become acquirers once a major clinical or commercial uncertainty is removed. If EscharEx delivers a strong Phase 3 outcome, that uncertainty drops dramatically.
